King Luther Capital Management Corp Acquires 16,030 Shares of Enovis Co. (NYSE:ENOV)

King Luther Capital Management Corp boosted its holdings in shares of Enovis Co. (NYSE:ENOV) by 15.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,874 shares of the company’s stock after acquiring an additional 16,030 shares during the period. King Luther Capital Management Corp owned about 0.22% of Enovis worth $6,715,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Fifth Third Bancorp boosted its holdings in shares of Enovis by 144.6% in the 3rd quarter. Fifth Third Bancorp now owns 587 shares of the company’s stock valued at $31,000 after buying an additional 347 shares in the last quarter. Principal Securities Inc. bought a new stake in shares of Enovis in the 4th quarter valued at about $41,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Enovis by 97.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock valued at $47,000 after purchasing an additional 417 shares during the last quarter. GAMMA Investing LLC purchased a new position in shares of Enovis in the 4th quarter valued at approximately $53,000. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Enovis in the 3rd quarter valued at approximately $82,000. 98.45% of the stock is currently owned by institutional investors.

Enovis Stock Performance

Shares of NYSE:ENOV traded down $0.22 during trading on Thursday, hitting $50.82. 38,004 shares of the stock traded hands, compared to its average volume of 485,217. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.10 and a quick ratio of 1.03. The company has a fifty day moving average price of $56.55 and a two-hundred day moving average price of $56.30. Enovis Co. has a 52-week low of $43.04 and a 52-week high of $66.14.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, May 2nd. The company reported $0.50 earnings per share for the quarter, meeting the consensus estimate of $0.50. The firm had revenue of $516.00 million during the quarter, compared to analyst estimates of $505.62 million. Enovis had a negative net margin of 4.51% and a positive return on equity of 3.98%. The business’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.44 EPS. On average, analysts predict that Enovis Co. will post 2.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Canaccord Genuity Group increased their price objective on shares of Enovis from $73.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Wells Fargo & Company increased their price objective on shares of Enovis from $73.00 to $79.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. Needham & Company LLC reissued a “buy” rating and set a $82.00 price target on shares of Enovis in a research report on Friday, May 3rd. Finally, Stephens initiated coverage on shares of Enovis in a research report on Tuesday, February 13th. They set an “overweight” rating and a $72.00 price target for the company. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $75.43.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.